NASDAQ$OKUR
OnKure Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
OKUR Q1 2024 — $1.24B revenue, 33.00 EPS
Any of these actions could negatively impact the Company’s business, results of operations, and future prospects. OnKure Therapeutics Inc reported Q1 2024 results. Diluted EPS came in at $33.00. Net income of $15.1M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.24B.
- Diluted EPS: $33.00.
- Net income: $15.1M.
- Operating income: $10K.
Headline financials
Revenue & EPS history
Reneo Pharmaceuticals · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.6%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+21.2%
Q2 2025
Best reaction
-10.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -15.0% | -6.3% | |
| Q3 2025 | -5.5% | -2.5% | -3.2% | |
| Q2 2025 | +21.2% | +24.6% | +20.2% | |
| Q1 2025 | +12.5% | +7.5% | +21.0% | |
| Q4 2024 | +3.7% | +4.8% | -40.0% | |
| Q3 2024 | +3.2% | +1.8% | -16.7% | |
| Q2 2024 | +9.7% | +15.7% | +5.2% | |
| Q1 2024 | +2.4% | +3.0% | +0.6% | |
| Q4 2023 | +3.0% | +3.6% | +1.2% | |
| Q3 2023 | -0.9% | +5.6% | +21.1% | |
| Q2 2023 | -6.3% | -15.1% | +7.1% | |
| Q1 2023 | -1.4% | -0.9% | +79.3% | |
| Q4 2022 | -10.3% | -1.0% | +65.1% | |
| Q3 2022 | -3.0% | -8.6% | -35.4% | |
| Q2 2022 | -3.0% | +4.1% | +34.6% | |
| Q1 2022 | -5.9% | -10.8% | -28.2% | |
| Q4 2021 | -1.4% | -6.8% | -34.7% | |
| Q3 2021 | +14.8% | +5.7% | -13.2% | |
| Q2 2021 | +0.1% | -3.2% | +2.0% | |
| Q4 2020 | +7.5% | +2.9% | -2.3% | |
| Q1 2021 | +7.5% | +2.9% | -2.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro